Pharsight

1. Hysingla Er patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP06706682A	2017-12-19	G. L. Pharma GmbH	Revoked
EP2005006983W	2009-10-13	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP2005006983W	2009-10-13	Ypsomed AG	Patent maintained as amended
EP04763833A	2008-03-27	Purdue Pharma LP	Opposition rejected
EP04763834A	2007-12-14	Purdue Pharma LP	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6488963	PURDUE PHARMA LP	Hot-melt extrudable pharmaceutical formulation	Jun, 2017 (6 years ago)
US9675611	PURDUE PHARMA LP	Methods of providing analgesia	Oct, 2020 (3 years ago)
US9060940	PURDUE PHARMA LP	Controlled release hydrocodone	Oct, 2020 (3 years ago)
US9198863	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2020 (3 years ago)
US9205056	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2020 (3 years ago)
US9682077	PURDUE PHARMA LP	Methods of providing analgesia	Oct, 2020 (3 years ago)
US9669024	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2020 (3 years ago)
US9517236	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2020 (3 years ago)
US9289391	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2020 (3 years ago)
US9572804	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2020 (3 years ago)
US9669023	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2020 (3 years ago)
US9056052	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2020 (3 years ago)
US9023401	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2020 (3 years ago)
US8647667	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2021 (2 years ago)
US6733783	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2021 (2 years ago)
US8551520	PURDUE PHARMA LP	Controlled release hydrocodone	Oct, 2021 (2 years ago)
US8361499	PURDUE PHARMA LP	Controlled release hydrocodone formulations	Oct, 2021 (2 years ago)
US8529948	PURDUE PHARMA LP	Pharmaceutical formulation containing gelling agent	Aug, 2022 (1 year, 8 months ago)
US10369109	PURDUE PHARMA LP	Abuse-proofed dosage form	Jun, 2023 (10 months ago)
US9675610	PURDUE PHARMA LP	Abuse-proofed dosage form	Jun, 2023 (10 months ago)
US10130591	PURDUE PHARMA LP	Abuse-proofed dosage form	Nov, 2023 (5 months ago)
US8309060	PURDUE PHARMA LP	Abuse-proofed dosage form	Nov, 2023 (5 months ago)
US11844865	PURDUE PHARMA LP	Abuse-proofed oral dosage form	Feb, 2025 (9 months from now)
US9775809	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9095614	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9545380	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9770416	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9095615	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9492390	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9492389	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9486412	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9492391	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US11304909	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9763933	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9486413	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US9084816	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US11304908	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (3 years from now)
US8808740	PURDUE PHARMA LP	Encased tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)
US9861584	PURDUE PHARMA LP	Tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)
US9872837	PURDUE PHARMA LP	Tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)
US9750703	PURDUE PHARMA LP	Encased tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)
US9572779	PURDUE PHARMA LP	Encased tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg, 60 mg, and 120 mg	15 Apr, 2015	1	01 Mar, 2021	21 Dec, 2031	Deferred
30 mg, 40 mg, 80 mg, and 100 mg	08 May, 2015	1	01 Mar, 2021	21 Dec, 2031	Deferred

Strength	Dosage	Availability
60MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
120MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
40MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
80MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
20MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
100MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

HYSINGLA ER family patents

2. Vantrela Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572803	TEVA BRANDED PHARM	Abuse resistant drug formulation	Sep, 2027 (3 years from now)
US9216176	TEVA BRANDED PHARM	Abuse resistant drug formulation	Sep, 2027 (3 years from now)
US8445018	TEVA BRANDED PHARM	Abuse resistant drug formulation	Jul, 2029 (5 years from now)

Market Authorisation Date: 17 January, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
60MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
90MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
45MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

VANTRELA ER family patents

3. Zohydro Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6228398	RECRO GAINESVILLE	Multiparticulate modified release composition	Nov, 2019 (4 years ago)
US6902742	RECRO GAINESVILLE	Multiparticulate modified release composition	Nov, 2019 (4 years ago)
US10456393	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US9610286	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US10322120	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US9333201	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US9265760	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US10028946	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US9421200	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US9433619	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US9339499	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US10722511	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US9326982	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (9 years from now)
US9713611	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (10 years from now)
US9452163	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (10 years from now)
US10092559	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (10 years from now)
US9132096	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (10 years from now)
US9486451	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (10 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 25, 2016

Market Authorisation Date: 25 October, 2013

Treatment: Treatment of pain in patients with hepatic impairment; Treatment of pain

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Pharsight

Drugs that contain Hydrocodone Bitartrate

1. Hysingla Er patents expiration

HYSINGLA ER family patents

2. Vantrela Er patents expiration

VANTRELA ER family patents

3. Zohydro Er patents expiration

ZOHYDRO ER family patents

Related content

Strength	Dosage	Availability
30MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
15MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
40MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
20MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
10MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued